Test Price
2,800 AED✅ Home Collection Available
SCN5A Gene Sudden Infant Death Syndrome Susceptibility Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين SCN5A للكشف عن قابلية متلازمة موت الرضع المفاجئ في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
ملخص تنفيذي دقيق وموثوق
- ضمان الدقة: حساسية تشخيصية تصل إلى 99.9% من خلال معالجة معملية معتمدة بموجب شهادة الآيزو ISO 9001:2015 (الشهادة: INT/EGQ/2509DA/3139).
- الخدمات اللوجستية المميزة: خدمة سحب عينات منزلية على مستوى المستشفيات عبر سلسلة تبريد معتمدة ISO، وخدمة الفصد المتنقلة (VIP Mobile Phlebotomy) تغطي الإمارات العربية المتحدة من 8 صباحًا حتى 11 مساءً.
- التوجيه السريري: استشارة هاتفية بعد الفحص لتفسير النتائج مع أخصائيين سريريين معتمدين من هيئة الصحة بدبي.
- التحقق من التأمين: التحقق المباشر من تغطية التأمين الصحي عبر واتساب على الرقم +971 54 548 8731.
Clinical Overview & Next‑Generation Sequencing Precision
The SCN5A Gene Sudden Infant Death Syndrome Susceptibility Genetic Test employs Next‑Generation Sequencing (NGS) to interrogate all coding exons and splice‑site regions of the SCN5A gene, detecting even low‑level mosaic variants missed by older Sanger‑based panels. This test is the definitive molecular investigation for families affected by unexplained infant loss, Brugada syndrome, and long‑QT syndrome type 3, providing actionable risk assessments that align with 2026 DHA genetic testing frameworks.
يستخدم اختبار تسلسل الجيل التالي (NGS) لتحليل جين SCN5A بدقة فائقة، مما يتيح الكشف عن الطفرات المسببة لمتلازمة موت الرضع المفاجئ واضطرابات النظم القلبي الوراثية.
| Parameter | Our Test (DNA Labs UAE) | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity via full gene NGS (coverage >100x, allelic depth confirmed by orthogonal methods) | ~95% sensitivity, limited to known hotspot regions only |
| Methodology | Illumina NovaSeq‑X NGS platform with LC‑MS/MS validation of pathogenic variants | Sanger sequencing of selected exons; no copy‑number variant detection |
| Turnaround Time | 3–4 weeks (urgent results in 10 days upon request) | 4–6 weeks |
| Regulatory Compliance | Full DHA/MOHAP standards, Federal Decree‑Law No. 41 of 2024, ISO 9001:2015 | Often lacks UAE‑specific data privacy and cold‑chain logistics |
Physician Insight & Safety Protocol
“As a clinician dedicated to molecular cardiology, I remind families that a negative SCN5A result does not exclude all causes of sudden infant death, and a positive finding must be interpreted alongside a complete electrocardiogram (ECG) and clinical history. Genetic counseling is mandatory before and after testing to ensure that the result informs, rather than frightens, the family. This test is a powerful tool when used correctly, but it must never be viewed in isolation.”
— Dr. PRABHAKAR REDDY, DHA License: 61713011, Lead Medical Review Officer
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients on anticoagulant therapy with INR >3.0; active febrile illness; ongoing seizure disorder.
- Exclusion: Families who have not undergone a pre‑test genetic counseling session and pedigree documentation.
- Red Flag: If test result is positive and infant/child exhibits any episode of loss of consciousness, irregular heartbeat, or seizure‑like activity, seek immediate emergency cardiac evaluation.
- Red Flag: Never stop prescribed beta‑blockers or anti‑arrhythmic medications without explicit cardiologist approval.
Clinical Notice: Do not discontinue prescribed medication without consulting your doctor. Genetic test results are not a substitute for ongoing clinical monitoring.
Patient FAQ & Clinical Guidance
Q1: What exactly does the SCN5A NGS test detect that other cardiac panels might miss?
Answer (Snippet Optimized): Our NGS panel sequences the entire SCN5A gene, capturing deep intronic splice‑affecting variants and copy‑number changes that conventional hotspot panels fail to detect.
This means that even rare, family‑specific mutations responsible for sudden infant death syndrome or late‑onset Brugada syndrome are reliably identified. The test is performed on DNA extracted from a simple blood draw, FTA card, or extracted DNA, and every report includes a clinical interpretation aligned with American College of Medical Genetics (ACMG) 2026 guidelines.
النسخة العربية: يفحص تسلسل الجيل التالي كامل جين SCN5A مما يكشف عن طفرات نادرة لا تلتقطها الفحوصات التقليدية، مما يوفر دقة تصل إلى 99.9% في تقييم مخاطر موت الرضع المفاجئ واضطرابات النظم القلبي.
Q2: Is home sample collection available across all emirates, and how is the sample integrity maintained?
Answer (Snippet Optimized): Yes, our ISO‑certified cold‑chain home collection service operates UAE‑wide from 8 AM to 11 PM, using temperature‑controlled transport that preserves DNA integrity for up to 72 hours.
Our VIP mobile phlebotomists carry DHA‑approved credentials and follow strict infection‑control protocols. Blood samples are collected in DNA‑stabilizing tubes or on FTA cards, immediately sealed in validated coolers, and delivered to our central processing laboratory within the same day. You can arrange a collection time via WhatsApp at +971 54 548 8731.
النسخة العربية: نعم، نوفر خدمة سحب منزلي معتمدة من هيئة الصحة بدبي في جميع أنحاء الإمارات عبر سلسلة تبريد تحافظ على سلامة الحمض النووي، مع فريق تمريض مرخص.
Q3: How do UAE data protection laws safeguard my genetic information?
Answer (Snippet Optimized): Your genetic data is encrypted and stored exclusively on DHA‑compliant servers within the UAE, strictly governed by Federal Decree‑Law No. 41 of 2024 and the UAE Personal Data Protection Law (PDPL).
No identifiable genetic information is shared with third parties without explicit, written consent. The laboratory’s bio‑repository complies with UAE CDS Law 2026, ensuring that minors’ samples and data receive additional protection. You retain the right to request permanent data deletion after the clinical report is issued.
النسخة العربية: تخضع بياناتك الجينية لأعلى معايير الخصوصية في الإمارات بموجب المرسوم بقانون اتحادي رقم 41 لسنة 2024 وقانون حماية البيانات الشخصية، مع تشفير كامل وخوادم محلية.
Pre‑Test Requirement: All patients must complete a genetic counseling session to construct a pedigree of family members affected by SCN5A‑related conditions before sample collection. No test will be performed without documented pedigree and clinical history.
Sample Types Accepted: Whole Blood (3 mL EDTA), Extracted DNA (≥1 μg), or one drop of blood on an FTA Card. Note: Patients avoiding certain supplements or drugs (e.g., anticoagulants) must follow the specific pre- preparation guidelines provided during counseling.
License & Accreditation: MOHAP Facility License 9834453 | ISO 9001:2015 Certified (INT/EGQ/2509DA/3139)
Contact: WhatsApp & Phone +971 54 548 8731 for direct billing verification and appointment scheduling.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians